Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction

被引:64
作者
Gahan, ME
Miller, F
Lewin, SR
Cherry, CL
Hoy, JF
Mijch, A
Rosenfeldt, F
Wesselingh, SL [1 ]
机构
[1] Monash Univ, Infect Dis Unit, Alfred Hosp, Dept Med, Prahran, Vic 3181, Australia
[2] Alfred Hosp, Cardiac Surg Res Unit, Prahran, Vic 3181, Australia
[3] Univ Melbourne, Royal Melbourne Hosp, Victorian Infect Dis Serv, Parkville, Vic 3052, Australia
[4] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia
关键词
mitochondrial DNA; mitochondrial toxicity; real-time PCR; mitochondrial DNA copy number; HIV; antiretrovirals;
D O I
10.1016/S1386-6532(01)00195-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: With decreased rates of HIV mortality and disease progression attributable to treatment with nucleoside analogue reverse transcriptase inhibitors (NRTIs), attention has now become focused on the toxicities of these forms of treatment. It is believed NRTIs cause a decrease in mitochondrial DNA (mtDNA) synthesis due to their inhibition of DNA polymerase gamma. This hypothesis is supported by in vitro data from muscle biopsies and human lymphoblastic cell lines. The resulting mitochondrial toxicity is thought to manifest itself in a variety of clinical symptoms including fatigue, fat wasting and peripheral neuropathy. A non-invasive test of mitochondrial toxicity is needed to assess toxicity and optimise HIV treatment strategies. Peripheral blood mononuclear cells (PBMC) and subcutaneous fat could be ideal and accessible sources of mtDNA for examining toxicity. Objectives: The objectives of this study were (a) to develop an assay to quantify the mtDNA copy number of PBMC and obtain reproducible results and (b) to establish the utility of subcutaneous fat as a source of mtDNA for quantification. Study Design: PBMC were isolated from blood by centrifugation over Ficoll-Paque((R)) and subcutaneous fat was obtained from two 3 mm, punch skin biopsies. Following DNA extraction, the mtDNA copy number in each sample was quantified by real-time polymerase chain reaction (PCR). Results: The real-time PCR assay was found to generate consistent and reproducible results with replicates of samples undertaken within the same run, and in two or more different runs, having a mean coefficient of variation of 11.3 and 17.2%, respectively. PBMC and subcutaneous fat contained 409 +/- 148 and 2042 +/- 391 copies of mtDNA per cell, respectively. Conclusions: From the work carried out it can be concluded that firstly, the real-time PCR assay generates consistent and reproducible results, and secondly that mtDNA can be extracted and quantified from PBMC and subcutaneous fat. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:241 / 247
页数:7
相关论文
共 17 条
  • [1] SEQUENCE AND ORGANIZATION OF THE HUMAN MITOCHONDRIAL GENOME
    ANDERSON, S
    BANKIER, AT
    BARRELL, BG
    DEBRUIJN, MHL
    COULSON, AR
    DROUIN, J
    EPERON, IC
    NIERLICH, DP
    ROE, BA
    SANGER, F
    SCHREIER, PH
    SMITH, AJH
    STADEN, R
    YOUNG, IG
    [J]. NATURE, 1981, 290 (5806) : 457 - 465
  • [2] DEPLETION OF MUSCLE MITOCHONDRIAL-DNA IN AIDS PATIENTS WITH ZIDOVUDINE-INDUCED MYOPATHY
    ARNAUDO, E
    DALAKAS, M
    SHANSKE, S
    MORAES, CT
    DIMAURO, S
    SCHON, EA
    [J]. LANCET, 1991, 337 (8740) : 508 - 510
  • [3] Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
    Brinkman, K
    Smeitink, JA
    Romijn, JA
    Reiss, P
    [J]. LANCET, 1999, 354 (9184) : 1112 - 1115
  • [4] Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
    Brinkman, K
    ter Hofstede, HJM
    Burger, DM
    Smeitinkt, JAM
    Koopmans, PP
    [J]. AIDS, 1998, 12 (14) : 1735 - 1744
  • [5] A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome
    Carr, A
    Miller, J
    Law, M
    Cooper, DA
    [J]. AIDS, 2000, 14 (03) : F25 - F32
  • [6] CHEN CH, 1991, MOL PHARMACOL, V39, P625
  • [7] HIV disease progression in Australia in the time of combination antiretroviral therapies
    Correll, PK
    Law, MG
    McDonald, AM
    Cooper, DA
    Kaldor, JM
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1998, 169 (09) : 469 - 472
  • [8] Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study
    Egger, M
    Hirschel, B
    Francioli, P
    Sudre, P
    Wirz, M
    Flepp, M
    Rickenbach, M
    Malinverni, R
    Vernazza, P
    Battegay, M
    Bernasconi, E
    Burgisser, P
    Erb, P
    Fierz, W
    Grob, P
    Gruninger, U
    Jeannerod, L
    Ledergerber, B
    Luthy, R
    Matter, L
    Opravil, M
    Paccaud, F
    Perrin, L
    Pichler, W
    Piffaretti, GC
    Rutschmann, O
    Zanetti, G
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117): : 1194 - 1199
  • [9] Real time quantitative PCR
    Heid, CA
    Stevens, J
    Livak, KJ
    Williams, PM
    [J]. GENOME RESEARCH, 1996, 6 (10): : 986 - 994
  • [10] Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1 infected individuals on prolonged effective antiretroviral therapy
    Lewin, SR
    Vesanen, M
    Kostrikis, L
    Hurley, A
    Duran, M
    Zhang, L
    Ho, DD
    Markowitz, M
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (07) : 6099 - 6103